De novo tuberculosis during infliximab therapy in a patient with Behçet disease: Case Reports;Tuberkulose Neuinfektion unter Infliximab bei einer Patientin mit Morbus Behçet

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 7, 2009, Pages 616-618

  Skvara, Hans ^a   Duschek, Nikolaus ^a   Karlhofer, Franz ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Beh et disease; Infli ximab; TNF alpha; Tuberculosis

Indexed keywords

COLCHICINE; CORTICOSTEROID; ETHAMBUTOL; INFLIXIMAB; ISONIAZID; METHOTREXATE; MOXIFLOXACIN; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN TISSUE; LUNG BIOPSY; MILIARY TUBERCULOSIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUBERCULIN TEST;

EID: 68149103285     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07040.x     Document Type: Article

References (13)

1. Keane, J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005 44 : 714 20.
2. Rott S, Mrowietz U. The use of infliximab in dermatology. J Dtsch Dermatol Ges 2007 5 : 655 60.
3. Stas P, D'Hoore A, Van Assche G, Ge-boes K, Steenkiste E, Penninckx F, Rutgeerts P, Vermeire S. Miliary tuberculosis following infliximab therapy for Crohn disease: A case report and review of the literature. Acta Gastroenterol Belg 2006 69 : 217 20.
4. Fidder HH, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Van Assche G, Vermeire S, Rutgeerts P. Long-Term Safety of Infliximab for the treatment of Inflammatory Bowel Disease: A Single Center Cohort Study. Gut 2008 : gut.2008.163642v2.
5. Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, Esteve M, Rodriguez-Carballeira M, Lacasa JM, Salvador G, Garau J. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2008.
6. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 345 : 1098 104.
7. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008 8 : 601 11.
8. Harris J, Hope JC, Keane J. Tumor Necrosis Factor Blockers Influence Macrophage Responses to Mycobacterium tuberculosis. J Infect Dis 2008 198 : 1842 50.
9. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008 59 : 209 17.
10. Theis VS, Rhodes JM. Review article: minimizing tuberculosis during antitumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008 27 : 19 30. (Pubitemid 350212629)
11. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, Matsushima T, Oka M. Clinical features of immunocom-promised and nonimmunocompromised patients with pulmonary tuberculosis. J Infect Chemother 2007 13 : 405 10.
12. Dheda K, Lalvani A, Miller RF, Scott G, Booth H, Johnson MA, Zumla A, Rook GA. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005 19 : 2038 41.
13. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006 7 : 56.